To include your compound in the COVID-19 Resource Center, submit it here.

Amid Onpattro launch, Alnylam raises $387.5M

Just over five months after gaining its first-ever approval of an RNAi therapy, Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) has raised $387.5

Read the full 207 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE